Loading
Latest filing published 14 Jun 2018 for IMV Inc. (formerly Immunovaccine Inc.), €7,325.
CTI Life Sciences Fund II, L.P. appears in our data through filings on IMV Inc. (formerly Immunovaccine Inc.) shares, published by SEDI. Between 8 June 2018 and 12 June 2018, the trades on record add up to 2 filings.
No open-market purchase appears, only 1 sale worth €7,325. Other entries cover 1 option exercise.
The latest filing, published on 14 June 2018, reports an open-market sale of €7,325 in IMV Inc. (formerly Immunovaccine Inc.). Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations